NXP-800 is under clinical development by Nuvectis Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NXP-800’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NXP-800 is under development for the treatment of solid tumors, ovarian clear cell carcinoma, endometroid ovarian cancers, fallopian tube, peritoneal cancer, cholangiocarcinoma, melanoma, gastric carcinoma and breast cancer. It is administered through oral route. The drug candidate acts by targeting heat shock transcription factor (HSF1).
Nuvectis Pharma overview
Nuvectis Pharma is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma is headquartered in Fort Lee, New Jersey, the US.
For a complete picture of NXP-800’s drug-specific PTSR and LoA scores, buy the report here.